Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 4,664 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)

NCT05099263
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Vivaer Arc Stylus
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
9
States / cities
Colorado Springs, Colorado • Chicago, Illinois • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

NCT03572049
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
SUBA itraconazole, Conventional itraconazole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Treatment of Critical Illness Polyneuromyopathy

NCT01058421
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
intensive physical therapy, control group
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • Denver, Colorado • Englewood, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 28, 2026, 5:09 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 28, 2026, 5:09 AM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Sonu for Pediatric Nasal Congestion

NCT06773013
View directory record Official record
Conditions
Nasal Congestion and Inflammations
Interventions
Acoustic Resonance (Sound) Therapy
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
12 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Portola Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 28, 2026, 5:09 AM EDT
No Longer Available No phase listed Expanded access

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Anti-Sars-CoV-2 Convalescent Plasma
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
U.S. locations
26
States / cities
Oceanside, California • San Diego, California • Fort Carson, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FLUAD® vs. Fluzone® High-Dose Study

NCT03183908
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug, Adverse Drug Event
Interventions
FLUAD®, Fluzone® High-Dose
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
757 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 28, 2026, 5:09 AM EDT
Withdrawn Phase 1 Interventional

Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study

NCT00431379
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Tenecteplase
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

NCT04397718
View directory record Official record
Conditions
COVID-19
Interventions
Degarelix, Saline
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 28, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

NCT05204888
View directory record Official record
Conditions
COPD
Interventions
myAirvo3, Pulse oximeter
Device
Lead sponsor
Temple University
Other
Eligibility
30 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Outcomes of Patients Not Responding to Antibiotics in the Community

NCT00245427
View directory record Official record
Conditions
Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions
all macrolide antibiotics, all beta-lactam antibiotics
Drug
Lead sponsor
CPL Associates
Other
Eligibility
Up to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 28, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

NCT04248868
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
The Bashir™ Endovascular Catheter, r-tPA
Device · Drug
Lead sponsor
Thrombolex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Intensive Versus Traditional Voice Therapy

NCT03129880
View directory record Official record
Conditions
Dysphonia
Interventions
Weekly Voice Therapy, Intensive Voice Therapy
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 28, 2026, 5:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

NCT01475162
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 5:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

NCT04037462
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Immunotherapy
Interventions
Dexamthasone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Completed No phase listed Observational

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
Genetic · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 28, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

NCT04410523
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Completed No phase listed Observational Results available

An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease

NCT03040674
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
Cell therapy
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 28, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed No phase listed Observational

Aging and Cancer Effects (ACE) Study

NCT00204880
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 28, 2026, 5:09 AM EDT